Restless legs syndrome can turn bedtime into hours of discomfort and movement. Anecdotes about cannabis relief have circulated for years, but controlled evidence has been scarce. A 2026 exploratory trial gives the subject a real data point—and a clear list of reasons not to overread it.
Eighteen participants received an oral-mucosal product containing 2.7 milligrams of THC and 2.5 milligrams of CBD per spray. Sixteen participants had multiple sclerosis. Symptom scores improved, but there was no placebo group and the sample was highly specific.
What the Investigators Observed
Participants used the balanced THC-CBD formulation in an open-label design, meaning they and the researchers knew the treatment was active. Scores on the International Restless Legs Syndrome scale improved significantly. That finding supports a larger randomized trial.
It does not show how much improvement came from the drug, expectation, attention from researchers, natural symptom variation, or changes in sleep and anxiety. Without a control group, those effects cannot be separated.
The Population Matters
Sixteen of the 18 participants had multiple sclerosis. Restless legs symptoms in that population may not behave like symptoms in the broader public. The study also used a particular balanced formulation, not any flower, gummy, CBD oil, or high-THC product marketed for sleep.
Start with the Diagnosis
Leg discomfort at night can have several causes. Iron deficiency, kidney disease, pregnancy, neuropathy, and medication effects may need attention. Some common drugs can worsen symptoms. A product that sedates a person without addressing the cause may make the night feel different while leaving the medical issue unresolved.
THC can also cause dizziness, anxiety, impaired balance, and next-day effects. CBD and THC may interact with medication. Those concerns matter for people with multiple sclerosis, mobility limitations, or several prescriptions.
The measured conclusion is encouraging: a small, carefully described study found enough improvement to justify better research. The next step is a randomized, placebo-controlled trial with a broader population, longer follow-up, and functional outcomes. Until then, cannabis for restless legs syndrome remains an experimental conversation with a clinician, not a proven bedtime remedy.